KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Payables (2016 - 2026)

Biogen has reported Payables over the past 18 years, most recently at $358.5 million for Q1 2026.

  • For Q1 2026, Payables fell 83.25% year-over-year to $358.5 million; the TTM value through Mar 2026 reached $358.5 million, down 83.25%, while the annual FY2025 figure was $432.0 million, 80.12% down from the prior year.
  • Payables for Q1 2026 was $358.5 million at Biogen, down from $432.0 million in the prior quarter.
  • Over five years, Payables peaked at $7.7 billion in Q2 2022 and troughed at $358.5 million in Q1 2026.
  • A 5-year average of $3.1 billion and a median of $2.1 billion in 2025 define the central range for Payables.
  • On a YoY basis, Payables climbed as much as 1954.89% in 2022 and fell as far as 95.02% in 2022.
  • Year by year, Payables stood at $6.8 billion in 2022, then increased by 8.4% to $7.3 billion in 2023, then tumbled by 70.4% to $2.2 billion in 2024, then tumbled by 80.12% to $432.0 million in 2025, then fell by 17.01% to $358.5 million in 2026.
  • Business Quant data shows Payables for BIIB at $358.5 million in Q1 2026, $432.0 million in Q4 2025, and $6.7 billion in Q3 2025.